Stephanie Galanie
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Protein Structure and Dynamics, SARS-CoV-2 and COVID-19 Research, Enzyme Catalysis and Immobilization, Microbial Metabolic Engineering and Bioproduction
Most-Cited Works
- → Complete biosynthesis of opioids in yeast(2015)979 cited
- → A microbial biomanufacturing platform for natural and semisynthetic opioids(2014)268 cited
- → Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals(2020)133 cited
- → High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor(2021)107 cited
- → Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2(2023)89 cited
- → Engineering biosynthetic enzymes for industrial natural product synthesis(2020)82 cited
- → Mesoscale porous silica as drug delivery vehicles: Synthesis, characterization, and pH-sensitive release profiles(2010)75 cited
- → Optimization of yeast-based production of medicinal protoberberine alkaloids(2015)71 cited
- → Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease(2021)57 cited
- → Structural and functional characterization of NEMO cleavage by SARS-CoV-2 3CLpro(2022)34 cited